Axsome Therapeutics Inc is trading 7.1% up at approximately $237–238 in pre-market trading after announcing a comprehensive settlement of all SUNOSI (solriamfetol) patent litigation.
- The resolution removes a key legal overhang on a core commercial product and clarifies intellectual property protections, reducing uncertainty regarding future revenue.
- Investors view the settlement as a significant de-risking event that protects SUNOSI cash flows from immediate generic competition.
- The news has triggered a strong recovery in the stock, which had experienced recent share price volatility prior to this announcement.